Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Ascending Doses of CMS-D008 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults and Adults Living With Overweight or Obesity

NCT07518589 is registered in ClinicalTrials.gov with Shenzhen Kangzhe Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07518589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07518589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Ascending Doses of CMS-D008 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults and Adults Living With Overweight or Obesity
Lead sponsor
Shenzhen Kangzhe Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 2, 2026
Completion date
December 10, 2027
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

evaluate the safety and tolerability, healthy and overweight or obese participants